Hematologic Malignancy, Hematopoietic Stem Cell Transplantation
Conditions
Brief summary
This is a study utilizing the Magnetic-activated cell sorting (CliniMACS®) Alpha-Beta T-cell (αβT)/Cluster of Differentiation 19 (CD19), also called B lymphocyte antigen CD19 depletion device for Children and Young Adults with Hematologic Malignancies undergoing alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT). Patients will receive an allogenic HSCT from a matched unrelated donor (MUD), mismatch unrelated donor (MMUD) or a mismatched related (haploidentical) donor. Patients will receive a granulocyte-colony stimulating factor (G-CSF) ± Plerixafor donor mobilized peripheral stem cell donor transplant following CliniMACS® αβT cell/CD19+B cell depletion. Cluster of Differentiation 34 (CD34) and αβT cell content of the graft is determined based on the transplant indication.
Interventions
DEVICECliniMACS®
CliniMACS® αβT cell/CD19+B cell depletion device for Children and Young Adults with Hematologic Malignancies undergoing alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)
Sponsors
Nationwide Children's Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 30 Years
Healthy volunteers
No
Inclusion criteria
* Age ≤ 30 years * Patients who will benefit from an allogenic stem cell transplant to treat underlying primary hematological malignancy and lacks a suitably available matched sibling donor. * Karnofsky Index or Lansky Performance Scale ≥ 60 % on pre-transplant evaluation. * Karnofsky scores must be used for patients \> 16 years of age and Lansky scores for patients ≤ 16 years of age. * Patient or legal guardian must give informed consent if patient is ≥ 18 years. Legal guardian must give informed consent (and patient must give assent if appropriate) if patient is \< 18 years. * Adequate organ function (within 4 weeks of initiation of preparative regimen). For patients receiving Myeloablative conditioning (MAC) on this platform, they should meet organ function to tolerate MAC. Similar if patients are receiving Reduced intensity conditioning (RIC). * High resolution human leukocyte antigen (HLA) available
Exclusion criteria
* Patient does not have a suitable donor who is willing and able (meets donor criteria). * Patient reports a history of allergic reactions to murine protein * Pregnant or lactating females are ineligible as many of the medications used in this protocol could be harmful to unborn children and infants. Female patients of childbearing potential females ≥11 years of age or post- menarche and should have a negative pregnancy test * Patients with HIV or uncontrolled fungal, bacterial or viral infections are excluded. Patients with history of fungal disease during induction therapy may proceed if they have a significant response to antifungal therapy with no or minimal evidence of disease remaining by CT evaluation. Viremia by Pluripotency Check (PCR) analysis is not considered an active infection but may require immediate viral prophylaxis. Patients with possible fungal infections must have had at least 2 weeks of appropriate anti-fungal therapy and be asymptomatic - * Patients receiving umbilical cord blood and matched sibling donor transplants
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| One-year overall survival of patients undergoing allogeneic HSCT using the T-Cell Receptor (TCR) αβ/CD19+ depleted platform and grafts from alternative donors (MUD, MMUD and haploidentical) | 1 year | One-year overall survival of patients undergoing allogeneic HSCT |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of final status graft failure | 1 year | Incidence of final status graft failure by 1 year |
| Incidence grade III-IV acute graft versus host disease (GVHD) | 1 year | Incidence grade III-IV acute graft versus host disease (GVHD) by 1 year |
| Neutrophil and platelet engraftment following TCR αβ/CD19+ depleted alternative donor (MUD, MMUD and haploidentical) HSCT | 100 days | Neutrophil and platelet engraftment by day 100 |
| 100 day and 1 year Transplant related mortality | 1 year | 100 day and 1 year Transplant related mortality by 1 year |
| 1 year Event free survival | 1 year | 1 year Event free survival |
| Incidence of chronic GVHD | 1 year | Incidence of chronic GVHD by 1 year |
Countries
United States
Contacts
Primary ContactClelie Peck
Backup ContactLauren Rayman
Outcome results
None listed